Highly Competitive Performance - High Throughput, Excellent Sample Preservation Rate & Detection Sensitivity
CE Registration Letter No.
NL-CA002-2022-66875 (Netherlands/CIBG)
Packaging Specifications
96 tests/box
● CVDs Remains the “Number One Killer”globally
Cardiovascular diseases (CVDs) are still the leading cause of death globally. The prevalence of CVDs risk factors such as dyslipidemia, hypertension, and diabetes are severe. There is an urgent need for advanced methodology for Early detectionand prevention.
● Lack of Reliable Screening Methods for Early CVDs
Routine blood lipid testing is poorly predictive of atherosclerotic cardiovascular disease (ASCVD). Even if the results of routine blood lipid testing are normal, the residual cardiovascular risk of ASCVD still exists.
● Precision Classifying of HDL Subfractions⸺The best sensitive marker for CVDs risk assessment
High-density lipoprotein (HDL) consists of particles of different sizes, which constitute subfractions with different functions. HDL-2b is a key protective factor for CVDs, while the increase of HDL-3 may imply the increased risk of CVDs. It is the most sensitive marker for CVDs risk assessment currently, which can be used for cardiovascular disease risk assessment at an early stage.
● Microchip Electrophoresis——Rapid classification of HDL subfractions
HDL is the plasma lipoprotein (5-12nm) with the smallest particle size(5-12nm). Traditional methods for separation and detection of HDL subfractions are cumbersome and have poor repeatability, which limits the basic research and clinical application of HDL subfractions.[2]
Ardent Biomed original The World's First Clinical Microfluidic Electrophoresis Product, which has the characteristics of accuracy, reliable, rapid and convenience. It realizes automatic interpretation of samples online, and becomes the optimal platform for HDL subfractions classification, filling the gap in the field of HDL subfractions detection in the world.
● Ardent Biomed Original Microfluidic Platform
Accurate Micrometer scale, nano escalation reaction
Reliable Good repeatability and high resolution
Rapid Test 12 samples in 30 minutes
Convenient Simple procedure
● Application Field
Prevention and early intervention of CVDs
CVDs control and individualized medicine
Basic research on lipoprotein and CVDs
Development and efficacy confirmation of new lipid-lowering drugs
Establishment and evaluation of animal models
● Reference
[1]Muller's et al: PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) sub-fractionation is independent of HDL cholesterol. Clin Chem Lab Med 2008;46(4):490‒498.
[2]Martin S S, Jones S R, Toth P P. High-density lipoprotein subfractions: current views and clinical practice applications[J]. Trends in Endocrinology & Metabolism, 2014, 25(7): 329-336.
[3]National Cardiovascular Disease Center. China cardiovascular health and disease report 2021 [M] Beijing: Science Press.
[4]Maigeng Z , Haidong W , Xinying Z , et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet (London, England), 2019, 394(10204): 1145-1158.
[5]Bays H E, Taub P R, Epstein E, et al. Ten things to know about ten cardiovascular disease risk factors[J]. American Journal of Preventive Cardiology, 2021, 5: 100149
[6]Ljs A , Celm B , Pjs C , et al. The Coronary Artery Risk Development In Young Adults (CARDIA) Study[J]. Journal of the American College of Cardiology, 2021, 78( 3):260-277.
[7]Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines[J]. American Heart Journal, 2009, 157(1):111-117.
[8]Junren Z, Runlin G, ShuiPing Z, et al. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016 revision)[J]. Chinese Journal of Circulation
